TROVE2 polyclonal antibody

Ro autoantigens are of clinical significance because antibodies directed against them are found in most patients with primary Sjogren syndrome, subacute cutaneous lupus erythematosus (SLE), neonatal lupus erythematosus, ANA-negative lupus erythematosus, and systemic lupus erythematosus-like disease secondary to homozygous C2 or C4 complement deficiency. Ro/SSA is a ribonucleoprotein that binds to autoantibodies in 35 to 50% of patients with SLE and in up to 97% of patients with Sjogren syndrome. The Ro/SSA particle consists of a single immunoreactive protein noncovalently bound with one of four small RNA molecules. Most anti-Ro/SSA-positive sera antibodies detect not only the main protein, but also a smaller Ro/SSA protein.